Treating accelerated and blast phase myeloproliferative neoplasms: Progress and challenges Review
| Authors: | Ajufo, H. O.; Waksal, J. A.; Mascarenhas, J. O.; Rampal, R. K. |
| Review Title: | Treating accelerated and blast phase myeloproliferative neoplasms: Progress and challenges |
| Abstract: | Myeloproliferative neoplasms (MPNs) are a group of clonal hematologic malignancies that include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). MPNs are characterized by activating mutations in the JAK/STAT pathway and an increased risk of transformation to an aggressive form of acute leukemia, termed MPN-blast phase (MPN-BP). MPN-BP is characterized by the presence of > 20% blasts in the blood or bone marrow and is almost always preceded by an accelerated phase (MPN-AP) defined as > 10-19% blasts in the blood or bone marrow. These advanced forms of disease are associated with poor prognosis with a median overall survival (mOS) of 3-5 months in MPN-BP and 13 months in MPN-AP. MPN-AP/BP has a unique molecular landscape characterized by increased intratumoral complexity. Standard therapies used in de novo acute myeloid leukemia (AML) have not demonstrated improvement in OS. Allogeneic hematopoietic stem cell transplant (HSCT) remains the only curative therapy but is associated with significant morbidity and mortality and infrequently utilized in clinical practice. Therefore, an urgent unmet need persists for effective therapies in this advanced phase patient population. Here, we review the current management and future directions of therapy in MPN-AP/BP. |
| Keywords: | polycythemia-vera; primary myelofibrosis; therapeutics; interferon-alpha; transformation; mdm2; stem-cell transplantation; antagonist; acute myeloid-leukemia; myeloproliferative neoplasms; small-molecule; novel; blast phase; available therapy; accelerated phase; inhibitor ruxolitinib |
| Journal Title: | Therapeutic Advances in Hematology |
| Volume: | 14 |
| ISSN: | 2040-6207 |
| Publisher: | Sage Publications |
| Date Published: | 2023-01-01 |
| Start Page: | 20406207231177282 |
| Language: | English |
| ACCESSION: | WOS:001011274800001 |
| DOI: | 10.1177/20406207231177282 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work